Latest Issue

Volume 9 Issue 4

Paper of the Month

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Ryan C, Leonardi CL, Krueger JG et al.
JAMA 2011;306:864–71. Rofecoxib, a nonsteroidal anti-inflammatory drug, is a prime example of a drug that continued to be prescribed for a considerable length of time – in this case to >80 million patients – despite warnings from preliminary data showing increased cardiovascular (CV) risks associated with the drug. A randomized controlled trial of 2586 patients ultimately demonstrated an excess of thrombotic events with rofecoxib relative to placebo, and the drug was withdrawn.
» Read an expert review of this paper

Webcast

  • Home
  • Home
  • Home
  • Home
  • Home
  • Home

READER POLL

IJAR Poll 3
How have the “Treat-to-Target” recommendations affected your day-to-day practice?






Powered by NetPolls

READER SURVEY

SUBMIT AN ARTICLE

OTHER REMEDICA JOURNALS

COMPASS PUBMED SEARCH

Enter your search terms below to search pubmed for articles